Conference Coverage

VIDEO: Dr. Walter M. Stadler gives take-home messages from ASCO 2015 GU sessions


 

AT THE 2015 ASCO ANNUAL MEETING

References

CHICAGO – Dr. Walter M. Stadler provides his take on ASCO 2015 presentations and discussions around genitourinary research, including practice-changing results on the use of chemotherapy for treating prostate cancer and the timing of androgen suppression. He also addresses the disappointing results for using precision medicine to treat bladder cancer versus the encouraging results from immunotherapy for both bladder and renal cell cancer. Dr. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago. He had no financial disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Recommended Reading

Health status, not age, key to treating prostate cancer in elderly
MDedge Internal Medicine
Active surveillance linked to greater risk of death in intermediate-risk prostate cancer
MDedge Internal Medicine
Bicalutamide improves OS in locally advanced prostate cancer
MDedge Internal Medicine
Testicular cancer history ups risk for higher-risk prostate cancer
MDedge Internal Medicine
Bladder cancer ‘no longer one single disease’
MDedge Internal Medicine
New drugs signal promise for rare leukemia, prostate cancer
MDedge Internal Medicine
AACR: Biomarker of response to olaparib found
MDedge Internal Medicine
Androgen deprivation linked to cognitive impairment
MDedge Internal Medicine
ASCO: Upfront chemo prolongs life in men with advanced, hormone-naive prostate cancer
MDedge Internal Medicine
AUA: Very low-risk prostate cancers cause few deaths over 15 years
MDedge Internal Medicine